Celcuity Inc. (CELC)
| Market Cap | 286.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.47M |
| Shares Out | 12.29M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $23.16 |
| Previous Close | $24.02 |
| Change ($) | -0.86 |
| Change (%) | -3.58% |
| Day's Open | 23.89 |
| Day's Range | 22.81 - 23.94 |
| Day's Volume | 86,030 |
| 52-Week Range | 4.46 - 28.10 |
As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).
- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, sug...
180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the company's chief scientific offi...
Celcuity broke out and soared to a nearly two-year high Friday after striking a licensing deal with Pfizer for a breast cancer treatment. Celcuity paid Pfizer $10 million in cash and stock.
Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a cel...
Celcuity Inc (NASDAQ: CELC) has entered into a global licensing agreement with Pfizer Inc (NYSE: PFE), granting Celcuity exclusive rights to Pfizer's gedatolisib. The pan-PI3K/mTOR inhibitor is currentl...
MINNEAPOLIS--(BUSINESS WIRE)--Celcuity reports preliminary data for gedatolosib and provides corporate update
MINNEAPOLIS--(BUSINESS WIRE)-- #cancer--Celcuity has entered a global licensing agreement with Pfizer granting exclusive rights to Pfizer's cancer drug gedatolisib for breast cancer.
Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clini...
MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and exp...
Celcuity Inc (NASDAQ: CELC) has priced its upsized underwritten public offering of 1.7 million shares at $14 per share, raising approximately $24 million in gross proceeds. The offer price is at an 11% ...
- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HE...
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2020 Results - Earnings Call Transcript
Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2020 Results - Earnings Call Transcript
Celcuity Inc. (CELC) CEO Brian Sullivan on Q4 2019 Results - Earnings Call Transcript
While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2019 Results - Earnings Call Transcript
Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
About CELC
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was found... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 20, 2017 |
| Stock Exchange NASDAQ | Ticker Symbol CELC |
Analyst Forecasts
According to 2 analysts, the average rating for Celcuity stock is "Buy." The 12-month stock price forecast is 30.00, which is an increase of 29.53% from the latest price.